Chimerix (NASDAQ:CMRX) Hits New 52-Week High – Still a Buy?

Chimerix, Inc. (NASDAQ:CMRX)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $8.47 and last traded at $8.47, with a volume of 1029993 shares changing hands. The stock had previously closed at $8.45.

Analyst Ratings Changes

A number of research firms have recently issued reports on CMRX. HC Wainwright reissued a “neutral” rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reaffirmed a “neutral” rating and set a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Up 0.1 %

The business has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $2.43. The stock has a market cap of $760.86 million, a P/E ratio of -9.00 and a beta of 0.32.

Insiders Place Their Bets

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last quarter. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

A number of hedge funds have recently bought and sold shares of CMRX. Bender Robert & Associates acquired a new position in Chimerix in the 4th quarter valued at approximately $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix during the fourth quarter worth about $59,000. Jane Street Group LLC acquired a new stake in Chimerix during the fourth quarter valued at approximately $62,000. Diadema Partners LP acquired a new stake in Chimerix during the fourth quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix in the 4th quarter worth approximately $130,000. 45.42% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.